Objective: Sex steroid hormones play a role in colorectal cancer (CRC) development, but little is known about their influence on tumor progression and metastasis. Because catechol-O-methyltransferase (COMT; 22q11.21) activity is an important component of estrogen-mediated carcinogenesis, we hypothesized that germline variation in COMT may be associated with CRC survival. Methods: We identified 10 single nucleotide polymorphisms that tagged variation across two isoforms of COMT in 2,458 women with CRC from the Nurses' Health Study, Postmenopausal Hormones Supplementary Study to the Colon Cancer Family Registry, VITamins And Lifestyle Study, and Women's Health Initiative. All four studies participated in the Genetics and Epidemiology of Colorectal Cancer Consortium.
R eproductive factors and postmenopausal hormone use are associated with the risk of developing colorectal cancer (CRC). 1<3 Estrogen receptor methylation occurs in the colon as part of the aging process, and receptor expression loss correlates with carcinogenic progression. 4, 5 The association between endogenous and exogenous hormones and CRC survival is less clear. 6<9 Although few hormone-related genes have been found to be associated with CRC risk, 10, 11 genetic studies of survival may inform estrogen-mediated metastatic mechanisms. 12 Catechol-O-methyltransferase (COMT; 22q11.21) is a key enzyme involved in the metabolism of catechol estrogens into methoxy estrogens. 13 Catechol estrogens have the potential to form depurinating DNA adducts 14<16 and to function in the development of estrogen-related cancers. 17 COMT has two major isoforms: a soluble cytoplasmic isoform (S-COMT) accounting for 995% of enzyme activity and a membranebound isoform (MB-COMT) encoded by 50 additional amino acids. 18 Both isoforms are expressed in the gut. 19 A common nonsynonymous single nucleotide polymorphism (SNP) at codon 108 of S-COMT and codon 158 of MB-COMT (Val108/158Met; rs4680) has been extensively characterized and is known to decrease enzyme activity. 20, 21 Urinary 22 and blood 23 concentrations of estrogen metabolites have been found to depend on Val108/158Met genotype, but not in all studies. 24 Epidemiologic studies (940) that have evaluated this variant with respect to breast cancer risk have been highly inconsistent, 25 and more comprehensive genotyping efforts suggest that COMT variants independent of Val108/158Met may be related to breast cancer risk. 26 Although polymorphism in this gene has also been linked to the risk of developing other hormonal cancers, including endometrial 27 and prostate cancers, 28 the few previous studies of COMT genotype and CRC risk have reported no meaningful association. 29<31 Little is known about whether catechol estrogens influence disease progression and metastasis. In studies of breast cancer, COMT genotype has been linked to advanced stage at diagnosis, 32 treatment-associated outcomes such as fatigue and pain tolerance, 33 and disease-specific survival. 34 Not all studies, however, have observed this, 35 including one that found survival differences for a variant of COMT other than Val108/158Met. 36 In this first evaluation of COMT genotype and CRC survival, we captured a common germline variation across the gene using data from four large epidemiologic studies in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO).
METHODS

Survival cohorts and follow-up
Mortality information was ascertained for 2,458 genotyped women who were diagnosed with incident invasive CRC after the age of 50 years. These women were participants in the (1) Nurses' Health Study (NHS), (2) Postmenopausal Hormones Supplementary Study to the Colon Cancer Family Registry (PMH-CCFR), (3) VITamins And Lifestyle (VITAL) Study, or (4) Women's Health Initiative (WHI). Study-specific data collection procedures have been documented previously. 37<42 All participants provided an informed consent form, and all studies were approved by their respective institutional review boards.
Relevant prediagnostic exposures, such as body mass index (BMI), smoking status, and hormone therapy, were harmonized from study-specific baseline or follow-up questionnaires by members of a GECCO committee. 43 Tumor characteristics were abstracted from medical records and/or cancer registry linkages. Tumor site was classified using International Classification of Diseases, Ninth Revision and International Classification of Diseases, Tenth Revision codes, and stage at diagnosis was harmonized to approximate categorizations of Surveillance Epidemiology and End Results summary stage. Vital status, dates, and causes of death were determined from medical records, state death certificates, and/or National Death Index linkage through mid-2008 for NHS, mid-2009 for WHI, and the end of 2009 for PMH-CCFR and VITAL.
COMT genotypes
Eleven tag-SNPs of COMT with a minor allele frequency (MAF) of 5% or higher and a linkage-disequilibrium threshold r 2 of 0.8 were selected using the Genome Variation Server. 44 Study-specific genotyping procedures have been previously published, 40, 41 and additional details are available in a similar survival analysis using the same samples. 12 WHI genotyped participants into two mutually exclusive sets: WHI set 1 (WHI1) and WHI set 2 (WHI2). All 11 SNPs were directly genotyped in PMH-CCFR using a GoldenGate assay (Illumina, San Diego, CA). All but two SNPs were available from the Illumina genomewide arrays used by NHS, VITAL, WHI1, and WHI2. We used a modest proxy for rs4646315 (rs4646312; r 2 = 0.3), but rs9332347 had no suitable proxy and was excluded. Missing genotypes were imputed with MaCH based on HapMap2. 45 
Statistical analyses
Survival time was calculated from the date of CRC diagnosis to the end of available follow-up or death from any cause (overall) or from CRC (CRC-specific). Of 2,726 women 50 years or older at diagnosis who had available genotype, we excluded those missing survival time (NHS, n = 97; VITAL, n = 5; WHI1, n = 25; WHI2, n = 43) and those missing stage (NHS, n = 34; PMH-CCFR, n = 2; VITAL, n = 1; WHI1, n = 5; WHI2, n = 53). Hazard ratios (HRs) and 95% CIs per minor allele were calculated from proportional hazards regression. Single-SNP models were adjusted for age at diagnosis and race (PMH-CCFR) or principal components of ancestry (NHS, WHI1, WHI2, and VITAL). We considered models with and without further adjustment for stage at diagnosis, as well as those additionally adjusted for prediagnostic BMI, smoking status, and hormone therapy.
In secondary exploratory analyses, we tested whether associations with CRC-specific and overall survival depended on BMI, smoking status, or postmenopausal hormone use before diagnosis by including SNP interactions in single-SNP models that adjusted for age at diagnosis, race/ancestry, and stage at diagnosis. Estimates were pooled across studies using inverse variance-weighted random-effects meta-analysis. We report uncorrected P values and Benjamini-Hochberg 46 false discovery rateYcorrected P values that account for multiple comparisons, with P FDR e 0.05 being statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC). All statistical tests were two-sided.
RESULTS
Of 2,458 women with CRC and available information on stage and survival time, 799 died of any cause (566 died of CRC) during a median follow-up of 7 years after diagnosis across all study samples (Table 1) . PMH-CCFR had the narrowest age range for study eligibility and included the youngest women accordingly. There were relatively few rectal cancers included in WHI1 by design. The observed MAF of evaluated SNPs ranged from 16% to 49%, which helped ensure a sufficient number of observed deaths for all possible genotypes.
No SNP-survival association reached statistical significance, accounting for multiple comparisons for CRC-specific or overall survival ( Table 2) . Estimates further adjusted for prediagnostic BMI, smoking status, and hormone therapy were similar (data not shown). None of the SNP interactions with prediagnostic BMI, smoking status, and hormone therapy achieved statistical significance for CRC-specific or overall survival (data not shown).
DISCUSSION
Aside from estrogen receptor silencing via methylation, 4 little is known about the role of estrogen and its metabolites in promoting or inhibiting tumor cell proliferation in the colon and rectum. COMT inactivates estrogen quinones responsible for oxidative DNA damage 47 and influences levels of proapoptotic estrogen metabolites such as 2-hydroxyestrone 48 Vboth phenotypes that may be associated with COMT polymorphism. 49 Our findings, however, do not support the hypothesis that common germline variations in COMT are related to CRC survival in postmenopausal women. Furthermore, genetic associations with survival time did not depend on prediagnostic BMI, smoking habits, and hormone useVfactors that have been independently linked to COMT genotype in previous studies. 22,23,50<52 Studies of COMT genotype and cancer risk and survival have been highly inconsistent. If at all, germline polymorphism in COMT probably explains only a small proportion of the variation in circulating hormone concentrations, 24 making it difficult to observe associations with downstream chronic disease outcomes. The large size of our study is its primary strength. Our meta-analysis had adequate statistical power to detect modest associations. Given MAFs (16%-49%) as observed in our samples (assuming a 75% 5-y overall survival, with 30% of deaths occurring during, at most, 20 y of follow-up for those homozygous for the major allele), we had approximately 90% statistical power to detect HRs per minor allele between 1.2 and 1.3 for an > of 0.05 in an additive model. At an > of 0.005, we had 90% power to detect HRs between 1.2 and 1.4 for this MAF range. Minimal detectable HRs for CRC-specific survival were slightly higher. Lastly, whereas previous investigations of COMT genotype and cancer outcomes have focused only on the Val108/158Met polymorphism, our tagging approach captured common variations across the gene.
Information on treatment was not available from the epidemiologic studies included in this analysis. Because treatment tends to be homogenous by stage, our stage-adjusted and stage-stratified analyses, however, may have some ability to account for confounding and effect modification by treatment. We considered only common SNPs with MAFs of 5% or higher; it remains unclear if rare variants of COMT are associated with CRC survival.
CONCLUSIONS
Our findings suggest that common SNPs in the gene for COMT may be unrelated to estrogen-mediated metastatic mechanisms for CRC. More comprehensive studies that include men, measure more and rarer variants, and evaluate intermediate clinical outcomes such as treatment tolerance may still be informative.
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